High-field MR Imaging in Migraine, Visual Snow and Epilepsy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorUniversity of Zurich

About this trial

In this project, the aim is to recruit patients with drug resistant epilepsy and those suffering from migraine. Interestingly, patients suffering from epilepsy are also more often reporting to suffer from migraine. The pathobiology is understudied, but it is believed that both etiologies results from brain networks changes. A clinical certified 7T Terra Siemens scanner will be employed to assess in all participants (including healthy controls) how the microstructure differs in disease specific areas. Patients will further be clinically assessed as well as undergo questionnaires.

Migraine is also a common comorbidity to visual snow syndrom and has been shown to impact similar brain regions. However, the pathophysiology is still understudied and a better understanding of the two diseases is needed.

Eligibility criteria

Qualifiers

Patient must be able to read and sign the informed consent form

Stable prophylactic medication for 2 months prior to MRI

Patients diagnosed with migraine (with or without aura, episodic or chronic). Diagnosis is ensured by clinical interview (at least 8 weeks prior to MRI). Also, patients complete a migraine questionnaire (HARDSHIP) (at least 8 weeks before MRI). Migraine frequency ≥ 2 migraine attacks/month.

Patients with drug resistent epilepsy accroding to ILAE crtieria

Disqualifiers

Treatment of migraine disease with Botox within < 4 months before baseline and during the study period

Pregnant or breastfeeding women

Intention during the course of the trial to become pregnant

Women with bilateral ovariectomy, with or without hysterectomy, and postmenopausal women (>2 years of age) are not considered childbearing.

Trial design

Treatments tested in this trial

  • Structural MRI
  • Quantitative MRI
  • Diffusion MRI
  • fMRI
  • MR Spectroscopy

Treatment groups

200 Participants
are divided into 4 treatment groups

Sponsors and collaborators

University of Zurich

Lead sponsor

Balgrist University Hospital

Collaborator